device ds2® elisa (DYNEX tech)
90
Structured Review
DYNEX tech
device ds2® elisa
Device Ds2® Elisa, supplied by DYNEX tech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ds2%C2%AE+elisa+system/device+ds2++elisa/pmc11992424__mmc2-262-12-15
Average 90 stars, based on 1 article reviews
Device Ds2® Elisa, supplied by DYNEX tech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ds2%C2%AE+elisa+system/device+ds2++elisa/pmc11992424__mmc2-262-12-15
Average 90 stars, based on 1 article reviews
device ds2® elisa - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Concentration Assay:Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: IgG against the surface S1 domain of the spike protein (S-IgG) and the internal nucleocapsid (N) protein (N-IgG) (Euroimmun, Lubeck, Germany) were measured (in EDTA plasma samples) at hospital admission and at 1, 2, 6 and 12 months after patients’ discharge, using commercial Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: The IFN-γ concentration released in the plasma fraction obtained after centrifugation of the three tubes was then measured by an enzyme-linked immunosorbent assay (Human interferon-gamma ELISA, Euroimmun, Lübeck, Germany) with an automated Article Title: Single Ad26.COV2.S Booster Dose Following Two Doses of BBIBP-CorV Vaccine Against SARS-CoV-2 Infection in Adults: Day 28 Results of a Phase 1/2 Open-Label Trial Article Snippet: The IFN-γ 647 concentration released in the plasma fraction after centrifugation of the tubes was then 648 measured by ELISA (Human IFN-γ ELISA, Euroimmun, Lübeck, Germany) with an Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: A Retrospective Study of Factors Contributing to the Performance of an Interferon-Gamma Release Assay Blood Test for Tuberculosis Infection. Article Snippet: METHODS: We conducted a retrospective analysis of 31 000 QFT-Plus samples collected from 26 000 subjects at a tertiary hospital in South Korea over a 4-year period and compared the rates of positivity and indeterminate results across diverse clinical situations.. We also analysed the contribution of the QuantiFERON TB2 tube to the test’s sensitivity and determined optimal cutoff values for 3 hematologic parameters to distinguish false-negative results.. These cutoff values were validated in a separate cohort of subjects with microbiologically confirmed subclinical TB. Article Title: Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study Article Snippet: IgG antibody plasma levels against the SARS-CoV-2 internal nucleocapsid (N) protein (N-IgG) (Anti-SARS-CoV-2-NCP IgG ELISA, Euroimmun, Lubeck, Germany) and surface S1 domain of the spike protein (S-IgG) (Anti-SARS-CoV-2 IgG ELISA, Euroimmun, Lubeck, Germany) were measured using commercial Centrifugation:Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: IgG against the surface S1 domain of the spike protein (S-IgG) and the internal nucleocapsid (N) protein (N-IgG) (Euroimmun, Lubeck, Germany) were measured (in EDTA plasma samples) at hospital admission and at 1, 2, 6 and 12 months after patients’ discharge, using commercial Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: The IFN-γ concentration released in the plasma fraction obtained after centrifugation of the three tubes was then measured by an enzyme-linked immunosorbent assay (Human interferon-gamma ELISA, Euroimmun, Lübeck, Germany) with an automated Article Title: Single Ad26.COV2.S Booster Dose Following Two Doses of BBIBP-CorV Vaccine Against SARS-CoV-2 Infection in Adults: Day 28 Results of a Phase 1/2 Open-Label Trial Article Snippet: The IFN-γ 647 concentration released in the plasma fraction after centrifugation of the tubes was then 648 measured by ELISA (Human IFN-γ ELISA, Euroimmun, Lübeck, Germany) with an Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: A Retrospective Study of Factors Contributing to the Performance of an Interferon-Gamma Release Assay Blood Test for Tuberculosis Infection. Article Snippet: METHODS: We conducted a retrospective analysis of 31 000 QFT-Plus samples collected from 26 000 subjects at a tertiary hospital in South Korea over a 4-year period and compared the rates of positivity and indeterminate results across diverse clinical situations.. We also analysed the contribution of the QuantiFERON TB2 tube to the test’s sensitivity and determined optimal cutoff values for 3 hematologic parameters to distinguish false-negative results.. These cutoff values were validated in a separate cohort of subjects with microbiologically confirmed subclinical TB. Article Title: Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study Article Snippet: IgG antibody plasma levels against the SARS-CoV-2 internal nucleocapsid (N) protein (N-IgG) (Anti-SARS-CoV-2-NCP IgG ELISA, Euroimmun, Lubeck, Germany) and surface S1 domain of the spike protein (S-IgG) (Anti-SARS-CoV-2 IgG ELISA, Euroimmun, Lubeck, Germany) were measured using commercial Enzyme-linked Immunosorbent Assay:Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: IgG against the surface S1 domain of the spike protein (S-IgG) and the internal nucleocapsid (N) protein (N-IgG) (Euroimmun, Lubeck, Germany) were measured (in EDTA plasma samples) at hospital admission and at 1, 2, 6 and 12 months after patients’ discharge, using commercial Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: The IFN-γ concentration released in the plasma fraction obtained after centrifugation of the three tubes was then measured by an enzyme-linked immunosorbent assay (Human interferon-gamma ELISA, Euroimmun, Lübeck, Germany) with an automated Article Title: Single Ad26.COV2.S Booster Dose Following Two Doses of BBIBP-CorV Vaccine Against SARS-CoV-2 Infection in Adults: Day 28 Results of a Phase 1/2 Open-Label Trial Article Snippet: The IFN-γ 647 concentration released in the plasma fraction after centrifugation of the tubes was then 648 measured by ELISA (Human IFN-γ ELISA, Euroimmun, Lübeck, Germany) with an Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: A Retrospective Study of Factors Contributing to the Performance of an Interferon-Gamma Release Assay Blood Test for Tuberculosis Infection. Article Snippet: METHODS: We conducted a retrospective analysis of 31 000 QFT-Plus samples collected from 26 000 subjects at a tertiary hospital in South Korea over a 4-year period and compared the rates of positivity and indeterminate results across diverse clinical situations.. We also analysed the contribution of the QuantiFERON TB2 tube to the test’s sensitivity and determined optimal cutoff values for 3 hematologic parameters to distinguish false-negative results.. These cutoff values were validated in a separate cohort of subjects with microbiologically confirmed subclinical TB. Article Title: Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study Article Snippet: IgG antibody plasma levels against the SARS-CoV-2 internal nucleocapsid (N) protein (N-IgG) (Anti-SARS-CoV-2-NCP IgG ELISA, Euroimmun, Lubeck, Germany) and surface S1 domain of the spike protein (S-IgG) (Anti-SARS-CoV-2 IgG ELISA, Euroimmun, Lubeck, Germany) were measured using commercial Clinical Proteomics:Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: IgG against the surface S1 domain of the spike protein (S-IgG) and the internal nucleocapsid (N) protein (N-IgG) (Euroimmun, Lubeck, Germany) were measured (in EDTA plasma samples) at hospital admission and at 1, 2, 6 and 12 months after patients’ discharge, using commercial Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: The IFN-γ concentration released in the plasma fraction obtained after centrifugation of the three tubes was then measured by an enzyme-linked immunosorbent assay (Human interferon-gamma ELISA, Euroimmun, Lübeck, Germany) with an automated Article Title: Single Ad26.COV2.S Booster Dose Following Two Doses of BBIBP-CorV Vaccine Against SARS-CoV-2 Infection in Adults: Day 28 Results of a Phase 1/2 Open-Label Trial Article Snippet: The IFN-γ 647 concentration released in the plasma fraction after centrifugation of the tubes was then 648 measured by ELISA (Human IFN-γ ELISA, Euroimmun, Lübeck, Germany) with an Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: A Retrospective Study of Factors Contributing to the Performance of an Interferon-Gamma Release Assay Blood Test for Tuberculosis Infection. Article Snippet: METHODS: We conducted a retrospective analysis of 31 000 QFT-Plus samples collected from 26 000 subjects at a tertiary hospital in South Korea over a 4-year period and compared the rates of positivity and indeterminate results across diverse clinical situations.. We also analysed the contribution of the QuantiFERON TB2 tube to the test’s sensitivity and determined optimal cutoff values for 3 hematologic parameters to distinguish false-negative results.. These cutoff values were validated in a separate cohort of subjects with microbiologically confirmed subclinical TB. Article Title: Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study Article Snippet: IgG antibody plasma levels against the SARS-CoV-2 internal nucleocapsid (N) protein (N-IgG) (Anti-SARS-CoV-2-NCP IgG ELISA, Euroimmun, Lubeck, Germany) and surface S1 domain of the spike protein (S-IgG) (Anti-SARS-CoV-2 IgG ELISA, Euroimmun, Lubeck, Germany) were measured using commercial Binding Assay:Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: IgG against the surface S1 domain of the spike protein (S-IgG) and the internal nucleocapsid (N) protein (N-IgG) (Euroimmun, Lubeck, Germany) were measured (in EDTA plasma samples) at hospital admission and at 1, 2, 6 and 12 months after patients’ discharge, using commercial Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: The IFN-γ concentration released in the plasma fraction obtained after centrifugation of the three tubes was then measured by an enzyme-linked immunosorbent assay (Human interferon-gamma ELISA, Euroimmun, Lübeck, Germany) with an automated Article Title: Single Ad26.COV2.S Booster Dose Following Two Doses of BBIBP-CorV Vaccine Against SARS-CoV-2 Infection in Adults: Day 28 Results of a Phase 1/2 Open-Label Trial Article Snippet: The IFN-γ 647 concentration released in the plasma fraction after centrifugation of the tubes was then 648 measured by ELISA (Human IFN-γ ELISA, Euroimmun, Lübeck, Germany) with an Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: A Retrospective Study of Factors Contributing to the Performance of an Interferon-Gamma Release Assay Blood Test for Tuberculosis Infection. Article Snippet: METHODS: We conducted a retrospective analysis of 31 000 QFT-Plus samples collected from 26 000 subjects at a tertiary hospital in South Korea over a 4-year period and compared the rates of positivity and indeterminate results across diverse clinical situations.. We also analysed the contribution of the QuantiFERON TB2 tube to the test’s sensitivity and determined optimal cutoff values for 3 hematologic parameters to distinguish false-negative results.. These cutoff values were validated in a separate cohort of subjects with microbiologically confirmed subclinical TB. Article Title: Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study Article Snippet: IgG antibody plasma levels against the SARS-CoV-2 internal nucleocapsid (N) protein (N-IgG) (Anti-SARS-CoV-2-NCP IgG ELISA, Euroimmun, Lubeck, Germany) and surface S1 domain of the spike protein (S-IgG) (Anti-SARS-CoV-2 IgG ELISA, Euroimmun, Lubeck, Germany) were measured using commercial Inhibition:Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: IgG against the surface S1 domain of the spike protein (S-IgG) and the internal nucleocapsid (N) protein (N-IgG) (Euroimmun, Lubeck, Germany) were measured (in EDTA plasma samples) at hospital admission and at 1, 2, 6 and 12 months after patients’ discharge, using commercial Article Title: Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Article Snippet: The IFN-γ concentration released in the plasma fraction obtained after centrifugation of the three tubes was then measured by an enzyme-linked immunosorbent assay (Human interferon-gamma ELISA, Euroimmun, Lübeck, Germany) with an automated Article Title: Single Ad26.COV2.S Booster Dose Following Two Doses of BBIBP-CorV Vaccine Against SARS-CoV-2 Infection in Adults: Day 28 Results of a Phase 1/2 Open-Label Trial Article Snippet: The IFN-γ 647 concentration released in the plasma fraction after centrifugation of the tubes was then 648 measured by ELISA (Human IFN-γ ELISA, Euroimmun, Lübeck, Germany) with an Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated Article Title: A Retrospective Study of Factors Contributing to the Performance of an Interferon-Gamma Release Assay Blood Test for Tuberculosis Infection. Article Snippet: METHODS: We conducted a retrospective analysis of 31 000 QFT-Plus samples collected from 26 000 subjects at a tertiary hospital in South Korea over a 4-year period and compared the rates of positivity and indeterminate results across diverse clinical situations.. We also analysed the contribution of the QuantiFERON TB2 tube to the test’s sensitivity and determined optimal cutoff values for 3 hematologic parameters to distinguish false-negative results.. These cutoff values were validated in a separate cohort of subjects with microbiologically confirmed subclinical TB. Article Title: Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study Article Snippet: IgG antibody plasma levels against the SARS-CoV-2 internal nucleocapsid (N) protein (N-IgG) (Anti-SARS-CoV-2-NCP IgG ELISA, Euroimmun, Lubeck, Germany) and surface S1 domain of the spike protein (S-IgG) (Anti-SARS-CoV-2 IgG ELISA, Euroimmun, Lubeck, Germany) were measured using commercial |